Enalare Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for patients suffering from life-threatening acute respiratory and critical care conditions, including respiratory depression caused by drug overdose, post-surgery, and other conditions. The Company is planning to initiate pivotal studies for its lead compound ENA-001 in the near term.

Pharmaceutical

Enalare Therapeutics

Herm Cukier

Mark Coleman

Timothy P. McGurrin

Robert Raffa

Marty Lutz

Joseph Pergolizzi

Frank Diana

Thomas Miller

Daniel Motto

Advisory Board

Leadership Team

Clinical Development and Regulatory Affairs

Teams at Enalare Therapeutics

Advisory Board

Leadership Team

Clinical Development and Regulatory Affairs